Next Article in Journal
Hyponatremia Promotes Cancer Growth in a Murine Xenograft Model of Neuroblastoma
Previous Article in Journal
Effect of Low Concentration of Nitroxides on SH-SY5Y Cells Transfected with the Tau Protein
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 23
10.3390/ijms242316678
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Expression Profiles of Genes Related to Development and Progression of Endometriosis and Their Association with Paraben and Benzophenone Exposure

by
Francisco M. Peinado
1,2,*,
Alicia Olivas-Martínez
1,2,
Inmaculada Lendínez
3,
Luz M. Iribarne-Durán
1,
Josefa León
1,4,5,
Mariana F. Fernández
1,2,6,7,
Rafael Sotelo
8,
Fernando Vela-Soria
1,
Nicolás Olea
1,6,7,9,
Carmen Freire
1,6,10,
Olga Ocón-Hernández
1,8 and
Francisco Artacho-Cordón
1,6,7,*
1
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain
2
Centre for Biomedical Research, University of Granada, 18016 Granada, Spain
3
General Surgery, San Cecilio University Hospital, 18016 Granada, Spain
4
Digestive Medicine Unit, San Cecilio University Hospital, 18012 Granada, Spain
5
CIBER Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain
6
CIBER Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
7
Radiology and Physical Medicine Department, University of Granada, 18016 Granada, Spain
8
Gynecology and Obstetrics Unit, San Cecilio University Hospital, 18016 Granada, Spain
9
Nuclear Medicine Unit, San Cecilio University Hospital, 18016 Granada, Spain
10
Legal Medicine, Toxicology and Physical Anthropology Department, University of Granada, 18071 Granada, Spain
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(23), 16678; https://doi.org/10.3390/ijms242316678
Submission received: 11 September 2023 / Revised: 30 October 2023 / Accepted: 17 November 2023 / Published: 23 November 2023
(This article belongs to the Section Molecular Biology)
Review Reports Versions Notes

Abstract

:
Increasing evidence has been published over recent years on the implication of endocrine-disrupting chemicals (EDCs), including parabens and benzophenones in the pathogenesis and pathophysiology of endometriosis. However, to the best of our knowledge, no study has been published on the ways in which exposure to EDCs might affect cell-signaling pathways related to endometriosis. We aimed to describe the endometriotic tissue expression profile of a panel of 23 genes related to crucial cell-signaling pathways for the development and progression of endometriosis (cell adhesion, invasion/migration, inflammation, angiogenesis, and cell proliferation/hormone stimulation) and explore its relationship with the exposure of patients to parabens (PBs) and benzophenones (BPs). This cross-sectional study included a subsample of 33 women with endometriosis from the EndEA study, measuring their endometriotic tissue expressions of 23 genes, while urinary concentrations of methyl-, ethyl-, propyl-, butyl-paraben, benzophenone-1, benzophenone-3, and 4-hydroxybenzophenone were determined in 22 women. Spearman’s correlations test and linear and logistic regression analyses were performed. The expression of 52.2% of studied genes was observed in >75% of endometriotic tissue samples and the expression of 17.4% (n = 4) of them in 50–75%. Exposure to certain PB and BP congeners was positively associated with the expression of key genes for the development and proliferation of endometriosis. Genes related to the development and progression of endometriosis were expressed in most endometriotic tissue samples studied, suggesting that exposure of women to PBs and BPs may be associated with the altered expression profile of genes related to cellular pathways involved in the development of endometriosis.

1. Introduction

Endometriosis is a gynecological disease characterized by the presence of endometrial-like tissue outside the uterine cavity, primarily in the abdominopelvic cavity (peritoneum, ovaries, or rectovaginal septum) [1,2]. This functionally active ectopic tissue is sensitive to hormonal stimulation and can originate cyclic bleeding, promoting the appearance of local inflammatory reactions and triggering pain (dysmenorrhea, dyspareunia, or chronic pelvic pain), gastrointestinal disorders, or infertility, among other maladies [3,4].
The pathogenesis and pathophysiology of endometriosis have yet to be fully elucidated, although various theories have been proposed. Increasing evidence has been published over recent years on the implication of endocrine-disrupting chemicals (EDCs) [5] in an increased risk of endometriosis, which has been associated with human exposure to several families of EDCs [6,7,8], including parabens (PBs) and benzophenones (BPs) [6]. PBs, which are widely used as preservatives in personal care products (PCPs), pharmaceuticals, and food [9], include methyl- (MeP), ethyl- (EtP), propyl- (PrP), and butyl-paraben (BuP) congeners. BPs, which frequently serve as UV-filters in PCPs [10], include benzophenone-1 (BP-1), benzophenone-3 (BP-3), and 4-hydroxybenzophenone (4-OHBP) congeners.
In vitro and in vivo studies have demonstrated the estrogen-like effects of PBs and BPs, supporting the hypothesis that they promote endometriosis, an estrogen-dependent disease [11,12]. EDC exposure has also been associated with inflammation and oxidative stress [13,14], although its role in the pathophysiology remains unknown. Five key steps in the development and progression of endometriotic lesions—cell adhesion to the peritoneum; invasiveness into the mesothelium; recruitment of inflammatory cells; angiogenesis in endometriotic tissue; and cell proliferation—have been previously described [15]. Changes in mediators of the corresponding cell-signaling pathways have been observed in studies of endometriosis [16,17,18,19,20,21,22,23,24,25]. Thus, in comparison to normal endometrial tissue, ectopic tissue has evidenced upregulation of the following: integrins and claudins, key members of tight junctions [16,17]; metalloproteases (MMPs), involved in extracellular matrix cleavage and therefore invasiveness [18,19]; proinflammatory interleukins [20,21]; certain angiogenesis-related genes [22,23]; and genes related to cell proliferation [24,25]. Currently, the identification of different biomarkers of endometriosis is of crucial importance due to the need for non-invasive diagnostic methods of the disease [26]. Additionally, these biomarkers could predict whether women will respond to first-line treatment for this disease. To our best knowledge, no study has been published on the ways in which exposure to EDCs might affect these cell-signaling pathways. Following the observation by our group that exposure to PBs and BPs is associated with endometriosis risk [6], the present study was designed to determine the expression profile of a panel of 23 genes related to five key cell-signaling pathways for endometriosis development (cell adhesion; invasion, migration and metastasis; inflammation; angiogenesis; and cell proliferation and hormone stimulation) in women with endometriosis and to explore its relationship with their exposure to PBs and BPs. These families of EDCs were selected in this study due to (i) the growing evidence of the relationship between the consumption of cosmetics and PCPs, human exposure to PBs and BPs, and adverse health effects; (ii) previous studies reporting positive associations between PB/BP exposure and endometriosis risk [6,8]; and (iii) the scarcity of information on PB/BP exposure-related adverse outcome pathways in endometriosis.

2. Results

2.1. Characteristics of the Study Population and Urinary PB and BP Concentrations

The sociodemographic and reproductive characteristics of all participants (n = 33) are summarized in Supplementary Table S1. Out of the 33 women in the study, an adequate sample for exposure and gene expression measurements was obtained from 22, whose characteristics are reported in Supplementary Table S2. The mean age of the entire study participants (n = 33) was 38.0 ± 7.3 years; 60.6% (n = 20) were in a normal weight range (BMI < 25 kg/m2), 57.6% (n = 19) lived in a rural area, 63.6% (n = 21) did not have a university degree, 72.7% (n = 24) were employed outside the home, 45.5% (n = 15) were nulliparous, 63.6% (n = 21) had moderate/severe menstrual bleeding, and 75.8% (n = 25) had a diagnosis of ovarian/peritoneal endometriosis, with 63.6% (n = 21) being in stage I/II (Supplementary Table S1).
Our group previously reported the urinary PB and BP concentrations obtained for participants in the EndEA study [6]. All compounds were detected in all samples from our subsample of 22 women (Supplementary Table S3). The PB and BP congeners with the highest concentrations were MeP and BP-3, respectively.

2.2. Gene Expression Levels and Associations with PB and BP Concentrations

Gene expression levels in the endometriotic tissues from the entire cohort are exhibited in Table 1, showing that 12 genes (52.2%) were expressed in >75% of samples and 4 (17.4%) in 50–75%. Both genes related to cell adhesion were expressed in all samples, whereas only four of the seven invasion-, migration-, and metastasis-related genes (MMP1, RRM2, RHOB, and SPRY2) and three of the five inflammation-related genes (IL1RL1, IL6ST, and NR3C1) were expressed in more than half of samples. Finally, all angiogenesis-related genes and three of the genes related to cell proliferation and hormonal stimulation (DUSP6, ERα and STAR) were expressed in more than half of samples. The sole difference in expression between endometriosis stages was observed for two genes related to the invasion, migration, and metastasis pathway (FUT8 and SPRY2 genes), which showed higher gene expression levels in patients with stages III/IV. In addition, a higher close-to-significant expression of DUSP6 (p-value = 0.092) was observed in patients with stages III/IV (Supplementary Table S4). Supplementary Table S5 summarizes the gene expression profile of the subset of women with assessed values of both paraben/benzophenone exposure and gene expression levels (n = 22).
Spearman correlation coefficients between PBs/BPs and gene expression levels (n = 22) are displayed in Supplementary Table S6. Associations between PB/BP exposure and gene expression levels (n = 22) are reported in Table 2, Table 3, Table 4, Table 5 and Table 6. Significant associations were also shown in dot plots (genes expressed in >75% of samples) and box plots (genes expressed in 25–75% of samples) (Supplementary Figures S1–S5). The concentration of at least one PB congener was associated with the expression of gene(s) involved in each of the five pathways under study, while BPs were associated with genes related to invasion, migration/metastasis, inflammation, cell proliferation, and hormonal stimulation cell-signaling pathways but not the adhesion and angiogenesis pathways.

2.2.1. Markers of Cell Adhesion

Urinary concentrations of MeP, BuP, and ∑PBs showed significant positive correlations with ectopic tissue ITGB2 and CLDN7 gene expression (Table 2 and Supplementary Figure S1). When concentrations were considered as dichotomous variables (higher vs. lower), expression of ITGB2 was related to higher concentrations of MeP, BuP, and ∑PBs, and its positive association with EtP was close to statistical significance (p-value = 0.091). A similar relationship was observed between ectopic expression of CLDN7 and higher concentrations of MeP, BuP, and ∑PBs. Furthermore, CLDN7 gene expression was greater for the third exposure tertile of both BuP and ΣPBs, with statistical significance in the case of BuP and almost reaching statistical significance in the case of ΣPBs (p-value = 0.066) (Supplementary Table S7). No significant associations were found between BP exposure and ITGB2 or CLDN7 gene expression levels.

2.2.2. Markers of Invasion, Migration, and Metastasis

Urinary MeP and ∑PBs concentrations were positively associated with the expression of MMP1 and RHOB genes, and EtP and BuP concentrations were also positively related to the expression of RHOB gene (Table 3 and Supplementary Figure S2). Similar associations were observed when exposure was dichotomized, with increased risk of detectable MMP1 and RHOB expression levels in patients with higher exposure to MeP and ∑PBs and of detectable RHOB expression in patients with higher exposure to BuP. In addition, RHOB gene expression levels gradually increased when BuP was categorized into tertiles. A similar trend was observed for tertiles of ∑PBs and MMP1 (Supplementary Table S7). Moreover, detectable expression of FUT8 was observed in the women with higher exposure to PrP, while the higher expression levels of RRM2 in women with a higher concentration of MeP was close to statistically significant (p-value = 0.088). By contrast, MeP and ∑PBs concentrations were inversely associated with the detectable expression of SPRY2. A positive association was found between concentrations of ∑BPs and detectable expression of MMP1. MMP7 expression was detected in <25% of the study population; therefore, no linear or logistic regression was performed.

2.2.3. Markers of Inflammation

MeP, BuP, and ∑PB concentrations were significantly correlated with NR3C1 and IL6ST expression levels, and higher MeP, BuP, and ∑PB concentrations were also correlated with IL6ST expression levels (Table 4 and Supplementary Figure S3). Women with higher concentrations of BuP also showed increased IL1RL1 expression, although statistical significance was not reached (p-value = 0.055). Moreover, the expression of IL6ST and NR3C1 gradually increased with higher tertiles of BuP concentrations (Supplementary Table S7). TNFRSF1B expression was positively associated with urinary concentrations of BP3 and ƩBPs, and a similar association was observed between TNFRSF1B and concentrations of BP3 and ƩBPs when the exposure was dichotomized, although the latter did not reach the statistical significance (p-value = 0.080). Higher IL1RL1 levels were also observed in the participants with higher 4-OHBP concentrations. IL1R2 expression was detected in <25% of the study population; therefore, no linear or logistic regression was performed.
Urinary concentrations of MeP and ∑PBs were significantly correlated with ANGPT1 exposure, both as a continuous and dichotomous variable (Table 5 and Supplementary Figure S4). MeP and ∑PBs were close to significantly associated with ANG expression levels (p-values = 0.062 and 0.063, respectively). PrP concentrations were positively associated with the expression of sVEGFR-1, and BuP showed a similar association when considered as a dichotomous variable. Finally, reduced VEGFA expression was observed in the women with higher EtP concentration, although statistical significance was not reached (p-value = 0.080). No association was observed between concentrations of BP congeners and the expression of angiogenesis-related genes, except for lower VEGFA expression in the women with higher concentrations of BP-1 and BP-3, although these associations did not reach statistical significance (p-values = 0.080 in both cases).
DUSP6 gene expression was inversely associated with concentrations of MeP and ƩPBs. ERα expression was significantly and positively related to MeP and ƩPBs concentrations, both as a continuous and dichotomous variable, and was also positively and close-to-significantly associated with EtP and BuP (p-values = 0.074 and 0.076, respectively). Lower STAR gene expression was associated with higher MeP concentrations, although statistical significance was not reached when considered as a continuous variable (p-value = 0.086), while STAR levels were positively associated with concentrations of BP-1 and 4-OHBP (Table 6 and Supplementary Figure S5). Expression of CYP19A1 and PGR was detected in <25% of the study population; therefore, no linear or logistic regression was performed.

3. Discussion

To the best of our knowledge, this is among the very first studies to describe the expression profile of key genes involved in the main molecular processes related to endometriosis in human endometriotic tissue and its potential association with exposure to EDCs. Most of the studied genes were expressed in the majority of samples, and exposure to certain PB and BP congeners was positively associated with the expression of genes involved in cell adhesion; invasion, migration, and metastasis; inflammation; angiogenesis; and cell proliferation and hormonal stimulation, critical molecular processes for the onset and progression of this disease. This evidence should be added to our previous report addressing the associations between PB/BP exposure and expression profiles of genes related to other cell molecular processes related to endometriosis, such as the cell cycle, cell differentiation, and lipid metabolism [27].
Adhesion of endometrial cells to the peritoneal surface is considered a primary hallmark of endometriosis in its initial stages [28]. Exposure to various PBs was associated with adhesion-related ITGB2 and CLDN7 genes in the present study, in line with recent in vitro findings of enhanced adhesive capacity in human umbilical vein endothelial cells after exposure to different EDCs [29]. Upregulation of CLDN7 has also been reported in ovarian cancer cell lines [30], although the evidence is contradictory, given that downregulation of CLDN7 has been observed in human endometriotic lesions [31] and endometrial cancer, promoting proliferation and metastasis [32].
The adhesion of endometrial cells to the peritoneal surface is followed by a process of invasion, migration, and metastasis that involves the overexpression of metalloproteinases [33]. MMP1 was expressed in most of the present endometriotic samples, in agreement with previous reports of MMP overexpression in women with endometriosis [34,35] and more severe stages of this disease [19,36]. An increase in MMP activation has been detected in ovarian cancer, enhancing cell invasiveness [30]. In the present investigation, MMP1 expression was positively associated with exposure to MeP, ∑PBs, and ƩBPs, which may therefore favor the invasion, migration, and metastasis of endometriotic cells. In vitro studies have linked PB exposure to increased MMP expression and activity in dermal fibroblasts [37] and breast cancer cells [38]. Exposure to other EDCs also increased MMP expression in ovarian cancer cell lines [39]. RHOB, FUT8, and RRM2 genes may also participate in invasion, migration, and metastasis. The expression of RHOB has not been described in endometriosis, but upregulation of this gene has been reported in human breast tumors [40]. The present study describes for the first time the presence of RHOB in endometriotic tissue and its positive association with exposure to most PB congeners studied. This suggests that exposure to these EDCs may contribute to the invasiveness of endometriotic tissue in a similar manner to the observed effects of EDCs on metastasis in breast cancer. FUT8 has not previously been studied in endometriosis tissue samples but has been implicated in the epithelial–mesenchymal transition and metastasis [41,42]. PrP concentrations were positively associated with FUT8 expression, suggesting that exposure to PrP may increase endometriotic tissue FUT8 and promote metastasis and progression to more advanced stages of disease. It is also suspected that RRM2 upregulation may promote cell invasion and metastasis in cancer and ovarian endometriosis [43,44]. Its expression was increased in the present women with higher MeP exposure, which may therefore play a potential role in boosting invasiveness. Finally, although the importance of SPRY2 in endometriosis is unknown, it plays a crucial role in the regulation of cancer cell invasion [45,46]. According to the present findings, MeP and ƩPBs might downregulate SPRY2 expression and thereby favor invasiveness and metastasis in women with endometriosis.
Another hallmark of endometriosis is a complex proinflammatory microenvironment, which favors cellular adhesion and invasion processes and the vascularization and proliferation of endometriotic lesions [47]. Upregulation of IL1RL1, IL6ST, TNFRSF1B, and NR3C1 has been described in women with endometriosis [48,49]. In line with the proposal that human exposure to PBs/BPs may be related to inflammation [14,50], the present results suggest that the upregulation of IL1RL1, IL6ST, TNFRSF1B, and NR3C1 genes associated with exposure to various congeners of PBs and BPs could contribute to the generation of an inflammatory environment in endometriotic tissue.
Angiogenesis plays an important role in the pathogenesis and pathophysiology of endometriosis, and various genes are involved in this molecular process [51]. Increased ANG, VEGFA, and sVEGFR-1 expression was previously observed in the peritoneal fluid of women with endometriosis [23,52]. In the present study, urinary concentrations of various PB congeners were positively associated with ANG, ANGPT1, and sVEGFR-1 expression. Despite associations not reaching statistical significance, exposure to BP-1 and BP-3 was unexpectedly related to downregulated levels of VEGFA. Although they were in accordance with a previous study carried out in Ehrlich ascites carcinoma and Dalton’s lymphoma ascites cells [53], others have found upregulation of VEGFA after exposure to other EDCs such as bisphenols in breast cancer cells [54] and upregulation of VEGFD in endometrial cells [55], indicating that our non-significant associations between BPs and VEGFA might be spurious. The present findings support the hypothesis that exposure to PBs could favor the development of pro-angiogenic properties via endometriotic lesions, as suggested by the observation of increased microvessel density after exposure to bisphenol A in a model of neuroblastoma [56].
Estradiol (E2) promotes the persistence, multiplication, and progression of endometriotic lesions, acting as a growth factor for this tissue [57], and endometriosis is closely associated with steroid metabolism and associated pathways [3,58]. E2 production requires the action of STAR, which facilitates the entry of cytosolic cholesterol into the mitochondrion, and CYP19A1, which is responsible for aromatization of androgens into estrogens [59,60]. In the present study, STAR gene was expressed in most of the ectopic tissue samples, and exposure to BP-1 and 4-OHBP was positively associated with STAR expression, indicating that exposure to these EDCs might be related to increased E2 production in endometriotic tissue. These results support the previous suggestion of a potential role for EDCs in the upregulation of CYP19A1 [61]. In contrast, a reduction in STAR expression was observed in the women with higher concentrations of MeP. Endometriotic lesions are very sensitive not only to the production of E2 but also to the presence of circulating estrogens. In this regard, E2 membrane receptors (ERα and ERβ) have been widely reported in endometriotic tissue [62], with some researchers describing ERβ as the predominant receptor on the cell surface [63]. Hence, although ERβ gene expression was not evaluated, ERα gene expression in endometriotic tissue was found to be positively related to exposure to most PB congeners examined, indicating that this exposure might contribute to the sensitivity of this tissue to circulating E2. The influence of BPs or PBs on ERα expression has not previously been studied, but the present results are in line with in vivo findings of ERα overexpression after exposure to BPA [64].
DUSP6 gene encodes a protein that counteracts cellular proliferation and is dysregulated in various diseases, including cancer. The number of cells expressing DUSP6 was reported to be lower in ectopic versus eutopic endometrium [65], suggesting this gene might also play a crucial role alongside E2 in enhancing cell proliferation in endometriotic tissue. In the present investigation, MeP and ΣPBs were associated with a lower expression of this gene in endometriotic tissue, suggesting that these EDCs might contribute to the downregulation of DUSP6 in this tissue.
Study limitations include the small sample size, reducing the statistical power, although it is highly challenging to gather endometriotic tissue samples for investigation. The limited amount of endometriotic tissue sample available prevented us from performing protein validation analysis to confirm the reported gene expression results. Furthermore, the utilization of spot urine samples prevented consideration of the variability in daily exposure to analytes with a relatively short elimination half-life. Nevertheless, samples were all first-morning urine samples taken during hospitalization before endometriosis surgery. In addition, only two families of EDCs were measured, with no evaluation of the combined effect of PBs and BPs alongside other EDCs. Furthermore, given the reported estrogenic/antiandrogenic effect of these compounds and possible similar underlying mechanisms of action [11,12], it is not possible to determine whether individual differences in these compounds could be the cause of the different associations found between EDC concentrations and gene expression levels. Finally, the ability to include covariates in regression analyses was limited by the small study population. Study strengths include the measurement, for the first time in endometriotic tissue, of numerous genes involved in cellular pathways related to the pathophysiology of endometriosis. Importantly, many cases revealed consistent associations between gene expression and exposure to certain PB/BP congeners. The combined investigation of biomarkers of exposure and potential biomarkers of effect yielded evidence of different pathways for adverse outcomes in endometriosis.

4. Material and Methods

4.1. Study Population and Sample Collection

This cross-sectional study, which forms part of the hospital-based case-control EndEA study, included 33 women with endometriosis undergoing surgery at the Gynecology and Obstetrics Units of San Cecilio and Virgen de las Nieves University Hospitals (Granada, Southern Spain) from January 2018 to July 2019 [6,7,27]. All cases were diagnosed with endometriosis via laparotomy or laparoscopic surgery and histological confirmation. Inclusion criteria were premenopausal status, age between 20 and 54 years, receipt of abdominal surgery, and body mass index (BMI) below 35 kg/m2. Exclusion criteria were history of cancer (except non-melanoma skin cancer), pregnancy at study enrolment, and inability to read and sign the informed consent document. Women were staged according to the Revised American Fertility Society classification [66]. Written informed consent was provided by all participants, and the study was approved by the Research Ethics Committee of Granada (0464-N-18).
Endometriotic tissue samples were gathered during surgery and kept in QIAazol reagent (Qiagen, Hilden, Germany) to ensure RNA stability, and first-morning spot urine samples were collected in fasting conditions (fasting time > 8 h) on the same day as the surgery and were kept in PB- and BP-free glass tubes. All samples were immediately stored at −80 °C at the Biobank of the Public Andalusian Health Care System until their analysis. The BMI of participants was calculated, and data were gathered on sociodemographic, lifestyle, and clinical variables from epidemiological and clinical questionnaires completed by participants and on surgical variables from questionnaires completed by surgeons (Supplementary Table S2). Endometriotic tissue samples were available from 33 participants, while urine samples were obtained from only 22 of them.

4.2. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Endometriotic tissue samples were maintained in QIAzol reagent (Qiagen, Hilden, Germany) during the homogenization process to ensure RNA stability. Total RNA was extracted from 30 mg of sample with the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Final RNA concentration and quality (260/280 ratio) were determined using a NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Total RNA (1000 ng) was transcribed into cDNA with the iScriptAdvanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions.
Real-time PCR was carried out with a CFX96 Real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA) using SsoAdvanced SYBR® Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). The manufacturer’s protocol was followed to measure the expression of 23 genes involved in the five cell-signaling pathways: cell adhesion (integrin beta-2 (ITGB2) and claudin 7 (CLDN7)); migration/invasion (matrix metallopeptidase 1 (MMP1), matrix metallopeptidase 7 (MMP7), fucosyltransferase 8 (FUT8), ribonucleotide reductase M2 (RRM2), midkine (MDK), ras homolog gene, family, member B (RHOB), and sprout homolog 2 (SPRY2)); inflammation (interleukin 1 receptor, type I (IL1R1), interleukin 1 receptor, type II (IL1R2), interleukin 6 cytokine family signal transducer (IL6ST), nuclear receptor subfamily 3 group C member 1 (NR3C1), and tumor necrosis factor receptor superfamily member 1B (TNFRSF1B)); angiogenesis (angiogenin (ANG), angiopoietin 1 (ANGPT1), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), and vascular endothelial growth factor A (VEGFA)); and cell proliferation/hormone stimulation (cytochrome P450 family 19 subfamily A member 1 (CYP19A1), dual specificity phosphatase 6 (DUSP6), estrogen receptor alpha (ERα), progesterone receptor (PGR), and steroidogenic acute regulatory protein (STAR)). Briefly, 10 μL SsoAdvanced Universal SYBR green mix, 1 μL cDNA (250 ng), and 1 μL of each PCR primer in 5 μmol L−1 were mixed together. Nuclease-free water was added to achieve the final volume of 20 μL. qPCR reaction conditions were the following: first, the initiation process took place, for which the temperature reaction reached a temperature of 95 °C for two minutes (1 cycle); subsequently, the denaturation process occurred through 40 cycles of 5 s at a temperature of 95 °C; next, the alignment and extension process took place, through 40 cycles of 60 s at a temperature of 65–95 °C; finally, to evaluate the reaction specificity of the assay, a cycle of 5 sec/step was carried out, at a temperature of 65–95 °C (0.5 °C increments), showing a melt curve for each of the genes in each sample analyzed. Primers used for these studies were purchased from Bio-Rad Laboratories (Hercules, CA, USA), and their assay ID, amplicon context sequence, amplicon length (bp), and chromosome location are detailed in Supplementary Table S8. Every mRNA primer used in this study was designed and experimentally tested by Bio-Rad Laboratories, generating an amplification plot using universal RNA, conducting a melt curve analysis, and calculating the efficiency and dynamic range from a seven-point standard curve. Specificity was determined by next-generation sequencing of the amplicon.
The criteria for the selection of these genes was based on previous evidence relating exposure to EDCs with the gene expression of these genes, their participation in the different cell-signaling pathways, and their relationship with endometriosis [67,68].
Gene expression was analyzed via Bio-Rad CFX 96 Manager Software to determine the cycle of quantification (Ct), and this was calculated using the 2−ΔΔCt method [69]. All values were normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA expression levels, calculating the difference corresponding to the quantification cycles between the target genes and GAPDH gene: ∆Ct = Ct (gene of interest)—Ct (GAPDH). Amplification efficiencies of the 23 primers used were ranged between 91 and 104%, being similar to that of the reference gene GAPDH (97%).

4.3. Chemical Analysis

Dispersive liquid–liquid microextraction (DLLME) and ultra-high-performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) were performed to determine urinary concentrations of MeP, EtP, PrP, BuP, BP-1, BP-3, and 4-OHBP, as previously described [70].
After thawing urine samples at room temperature and centrifuging at 2600× g for 10 min, 1.0 mL was taken for analysis. The total amount of these benzophenones and parabens (free and conjugated) was obtained by enzymatically treating samples with an enzyme solution of β-glucuronidase/sulfatase, pre-prepared by dissolving 10 mg of β-glucuronidase/sulfatase (3·106 U g solid−1) in 15 mL of 1M ammonium acetate/acetic acid buffer solution (pH 5.0). Enzymatically treated samples were incubated at 37 °C for 24 h. Next, 20 μL of standard replacement solution (5 mg/L of EP_13C6, 2 mg/L of BPA-D16, and 2 mg/L of BP-d10) were added, and samples were diluted with 10 mL of 10% aqueous NaCl solution (pH 2.0, adjusted with 0.5 M HCl). Samples were then mixed with a solution of 1 mL of acetone (dispersing solvent) and 0.5 mL of trichloromethane (extraction solvent), shaken manually for 30 s, and centrifuged at 4000× g for 10 min. The organic phase was then collected with care from the bottom of the glass tube using a 1 mL pipette and was placed in 2 mL glass vials. All of the extracted fluid was evaporated under a nitrogen stream, and the residue was dissolved with 100 μL of an acetonitrile/water mixture (0.1% ammonia, 70:30 [v/v]) and vortexed for 30 s. The extract was then ready for analysis via UHPLC-MS/MS. The limit of detection (LOD) was determined as the minimum detectable amount of analyte, with a signal-to-noise ratio ≥ 3. LODs were 0.05 ng/mL for BP-1, 0.06 ng/mL for BP-3 and 4-OHBP, and 0.10 ng/mL for MeP, EtP, PrP, and BuP.

4.4. Statistical Analysis

In a descriptive analysis, arithmetic means and standard deviations were calculated for continuous variables and relative frequencies for categorical variables. Urinary concentrations of PBs, BPs, and gene expression levels were summarized as arithmetic means with standard deviations and as 25, 50, and 75 percentiles. The Shapiro–Wilk test was applied to check the normality of variable distributions, and data found to be non-normally distributed underwent logarithmic transformation.
Spearman’s rank correlation coefficient was used to evaluate monotonic correlations between urinary concentrations of PBs/BPs and the expression of genes with detection/expression frequencies above 75%. Simple linear regression models were also developed to evaluate the relationship between PB/BP exposure and gene expression levels, expressing the results as β with 95% confidence intervals. In parallel, simple linear regression models were constructed after patient stratification (i) into lower or higher PB and BP exposure, i.e., below or above the median concentration of each congener; and (ii) into low, moderate, and high exposure, based on tertiles of PB and BP concentrations. Genes expressed in 25–75% of samples were considered as dichotomous variables (detected/not detected), and simple logistic regression models were used to evaluate their association with PBs and BPs (considering assumptions of each regression modality), while no analyses were performed on genes expressed in <25% of samples.
Statistical analysis was performed with SPSS Statistics 23.0 (IBM, Armonk, NY, USA) analysis, and the level of significance was p < 0.05 in all tests; however, associations with p-values between 0.05 and 0.10 are cautiously considered, given the limited sample size. Due to sample availability, descriptive analysis on sociodemographic/gynecologic characteristics and gene expression profiles were summarized from the whole cohort (n = 33), while urinary concentrations of PBs/BPs and the associations between expression profiles and exposure were accomplished with data from the subset of women with both samples collected (n = 22).

5. Conclusions

Genes related to the development and progression of endometriosis were expressed in most of this series of endometriotic tissue samples. The results obtained indicate that the exposure of women to PBs and BPs may be associated with the expression of genes involved in different molecular processes that play key roles in the development of endometriosis, including cell adhesion; invasion, migration, and metastasis; inflammation; angiogenesis; and cell proliferation and hormonal stimulation. Given the novelty of these results, further studies with larger sample sizes are warranted in order to confirm the impact of human exposure to EDCs on the pathophysiology of endometriosis.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms242316678/s1.

Author Contributions

F.M.P.: Investigation, Formal analysis, Writing—original draft; A.O.-M.: Investigation, Formal analysis; I.L.: Resources, Writing—Review and Editing; L.M.I.-D.: Investigation, J.L.: Investigation; Writing—Review and Editing; M.F.F.: Writing—Review and Editing; R.S.: Resources, Writing—Review and Editing; F.V.-S.: Investigation; N.O.: Writing—Review and Editing; C.F.: Investigation, Writing—Review and Editing; O.O.-H.: Conceptualization, Supervision, Funding acquisition, Writing—Review and Editing; F.A.-C.: Conceptualization, Methodology, Supervision, Formal analysis, Funding acquisition; Writing—Review and Editing. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), which funds the open access fee. It was also supported by a grant from the Spanish Ministry of Health (FIS PI17/01743) and the “Antonio Chamorro/Alejandro Otero” Research Chair, the European Union Commission (EU’s Horizon Europe research and innovation programme under Grant Agreement No. 101057014, PARC), and the Spanish Ministry of Health (PI16/01820, PI16/01812, and PI17/01526).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Acknowledgments

The authors are grateful to the Carlos III Institute of Health (ISCIII) for the predoctoral research contracts (IFI18/00052, FI21/00236, and FI17/00316) granted to P.F.M., O.-M.A., and I.-D.L.M., respectively, the Miguel Servet type II contract granted to F.C. (CPII21/00014), and the “Servicio Andaluz de Salud” (SAS) for the “Refuerzo de la Actividad Investigadora” research grant granted to O.N. (Exp. A1-0047-2021). The authors gratefully acknowledge the editorial assistance of Richard Davies. This paper is part of the PhD thesis developed by P.F.M. under the “Clinical Medicine and Public Health Program” of the University of Granada.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Giudice, L.C. Clinical practice. Endometriosis. N. Engl. J. Med. 2010, 362, 2389–2398. [Google Scholar] [CrossRef]
  2. Vercellini, P.; Viganò, P.; Somigliana, E.; Fedele, L. Endometriosis: Pathogenesis and treatment. Nat. Rev. Endocrinol. 2014, 10, 261–275. [Google Scholar] [CrossRef] [PubMed]
  3. Giudice, L.C.; Kao, L.C. Endometriosis. Lancet 2004, 364, 1789–1799. [Google Scholar] [CrossRef]
  4. Eskenazi, B.; Warner, M.L. Epidemiology of endometriosis. Obstet. Gynecol. Clin. N. Am. 1997, 24, 235–258. [Google Scholar] [CrossRef] [PubMed]
  5. Signorile, P.G.; Viceconte, R.; Baldi, A. New Insights in Pathogenesis of Endometriosis. Front. Med. 2022, 9, 879015. [Google Scholar] [CrossRef] [PubMed]
  6. Peinado, F.M.; Ocón-Hernández, O.; Iribarne-Durán, L.M.; Vela-Soria, F.; Ubiña, A.; Padilla, C.; Mora, J.C.; Cardona, J.; León, J.; Fernández, M.F.; et al. Cosmetic and personal care product use, urinary levels of parabens and benzophenones, and risk of endometriosis: Results from the EndEA study. Environ. Res. 2021, 196, 110342. [Google Scholar] [CrossRef] [PubMed]
  7. Peinado, F.M.; Lendínez, I.; Sotelo, R.; Iribarne-Durán, L.M.; Fernández-Parra, J.; Vela-Soria, F.; Olea, N.; Fernández, M.F.; Freire, C.; León, J.; et al. Association of Urinary Levels of Bisphenols A, F, and S with Endometriosis Risk: Preliminary Results of the EndEA Study. Int. J. Environ. Res. Public Health 2020, 17, 1194. [Google Scholar] [CrossRef] [PubMed]
  8. Kunisue, T.; Chen, Z.; Louis, G.M.B.; Sundaram, R.; Hediger, M.L.; Sun, L.; Kannan, K. Urinary concentrations of benzophenone-type UV filters in U.S. women and their association with endometriosis. Environ. Sci. Technol. 2012, 46, 4624–4632. [Google Scholar] [CrossRef]
  9. Błędzka, D.; Gromadzińska, J.; Wąsowicz, W. Parabens. From environmental studies to human health. Environ. Int. 2014, 67, 27–42. [Google Scholar] [CrossRef]
  10. Kim, S.; Choi, K. Occurrences, toxicities, and ecological risks of benzophenone-3, a common component of organic sunscreen products: A mini-review. Environ. Int. 2014, 70, 143–157. [Google Scholar] [CrossRef] [PubMed]
  11. Charles, A.K.; Darbre, P.D. Combinations of parabens at concentrations measured in human breast tissue can increase proliferation of MCF-7 human breast cancer cells. J. Appl. Toxicol. JAT 2013, 33, 390–398. [Google Scholar] [CrossRef] [PubMed]
  12. Molina-Molina, J.M.; Escande, A.; Pillon, A.; Gomez, E.; Pakdel, F.; Cavaillès, V.; Olea, N.; Aït-Aïssa, S.; Balaguer, P. Profiling of benzophenone derivatives using fish and human estrogen receptor-specific in vitro bioassays. Toxicol. Appl. Pharmacol. 2008, 232, 384–395. [Google Scholar] [CrossRef]
  13. Thompson, P.A.; Khatami, M.; Baglole, C.J.; Sun, J.; Harris, S.A.; Moon, E.Y.; Al-Mulla, F.; Al-Temaimi, R.; Brown, D.G.; Colacci, A.; et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis 2015, 36 (Suppl. S1), S232–S253. [Google Scholar] [CrossRef] [PubMed]
  14. Watkins, D.J.; Ferguson, K.K.; Del Toro, L.V.A.; Alshawabkeh, A.N.; Cordero, J.F.; Meeker, J.D. Associations between urinary phenol and paraben concentrations and markers of oxidative stress and inflammation among pregnant women in Puerto Rico. Int. J. Hyg. Environ. Health 2015, 218, 212–219. [Google Scholar] [CrossRef] [PubMed]
  15. Seli, E.; Berkkanoglu, M.; Arici, A. Pathogenesis of endometriosis. Obstet. Gynecol. Clin. N. Am. 2003, 30, 41–61. [Google Scholar] [CrossRef] [PubMed]
  16. Li, Q.; Xi, M.; Shen, F.; Fu, F.; Wang, J.; Chen, Y.; Zhou, J. Identification of Candidate Gene Signatures and Regulatory Networks in Endometriosis and its Related Infertility by Integrated Analysis. Reprod. Sci. 2022, 29, 411–426. [Google Scholar] [CrossRef] [PubMed]
  17. Horné, F.; Dietze, R.; Berkes, E.; Oehmke, F.; Tinneberg, H.R.; Meinhold-Heerlein, I.; Konrad, L. Impaired Localization of Claudin-11 in Endometriotic Epithelial Cells Compared to Endometrial Cells. Reprod. Sci. 2019, 26, 1181–1192. [Google Scholar] [CrossRef]
  18. Gottschalk, C.; Malberg, K.; Arndt, M.; Schmitt, J.; Roessner, A.; Schultze, D.; Kleinstein, J.; Ansorge, S. Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis. Adv. Exp. Med. Biol. 2000, 477, 483–486. [Google Scholar] [PubMed]
  19. Matsuzaki, S.; Maleysson, E.; Darcha, C. Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. Hum. Reprod. 2010, 25, 742–750. [Google Scholar] [CrossRef] [PubMed]
  20. Kato, T.; Yasuda, K.; Matsushita, K.; Ishii, K.J.; Hirota, S.; Yoshimoto, T.; Shibahara, H. Interleukin-1/-33 Signaling Pathways as Therapeutic Targets for Endometriosis. Front. Immunol. 2019, 10, 2021. [Google Scholar] [CrossRef] [PubMed]
  21. Mu, F.; Harris, H.R.; Rich-Edwards, J.W.; Hankinson, S.E.; Rimm, E.B.; Spiegelman, D.; Missmer, S.A. A Prospective Study of Inflammatory Markers and Risk of Endometriosis. Am. J. Epidemiol. 2018, 187, 515–522. [Google Scholar] [CrossRef] [PubMed]
  22. Machado, D.E.; Berardo, P.T.; Palmero, C.Y.; Nasciutti, L.E. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J. Exp. Clin. Cancer Res. CR 2010, 29, 4. [Google Scholar] [CrossRef] [PubMed]
  23. Cho, S.; Choi, Y.S.; Jeon, Y.E.; Im, K.J.; Choi, Y.M.; Yim, S.Y.; Kim, H.; Seo, S.K.; Lee, B.S. Expression of vascular endothelial growth factor (VEGF) and its soluble receptor-1 in endometriosis. Microvasc. Res. 2012, 83, 237–242. [Google Scholar] [CrossRef] [PubMed]
  24. Szaflik, T.; Smolarz, B.; Mroczkowska, B.; Kulig, B.; Soja, M.; Romanowicz, H.; BryŚ, M.; Forma, E.; SzyŁŁo, K. An Analysis of ESR2 and CYP19A1 Gene Expression Levels in Women with Endometriosis. In Vivo 2020, 34, 1765–1771. [Google Scholar] [CrossRef] [PubMed]
  25. Bulun, S.E.; Cheng, Y.H.; Pavone, M.E.; Xue, Q.; Attar, E.; Trukhacheva, E.; Tokunaga, H.; Utsunomiya, H.; Yin, P.; Luo, X.; et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin. Reprod. Med. 2010, 28, 36–43. [Google Scholar] [CrossRef] [PubMed]
  26. Gupta, D.; Hull, M.L.; Fraser, I.; Miller, L.; Bossuyt, P.M.; Johnson, N.; Nisenblat, V. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst. Rev. 2016, 4, Cd012165. [Google Scholar] [CrossRef]
  27. Peinado, F.M.; Olivas-Martínez, A.; Iribarne-Durán, L.M.; Ubiña, A.; León, J.; Vela-Soria, F.; Fernández-Parra, J.; Fernández, M.F.; Olea, N.; Freire, C.; et al. Cell cycle, apoptosis, cell differentiation, and lipid metabolism gene expression in endometriotic tissue and exposure to parabens and benzophenones. Sci. Total Environ. 2023, 879, 163014. [Google Scholar] [CrossRef]
  28. Jensen, J.R.; Coddington, C.C., 3rd. Evolving spectrum: The pathogenesis of endometriosis. Clin. Obstet. Gynecol. 2010, 53, 379–388. [Google Scholar] [CrossRef]
  29. Kenda, M.; Fonović, U.P.; Kos, J.; Dolenc, M.S. The effect of endocrine disrupting chemicals on the vitronectin-receptor (integrin α(v)β(3))-mediated cell adhesion of human umbilical vein endothelial cells. Toxicol. Vitr. Int. J. Publ. Assoc. BIBRA 2022, 79, 105275. [Google Scholar] [CrossRef]
  30. Dahiya, N.; Becker, K.G.; Wood, W.H., 3rd; Zhang, Y.; Morin, P.J. Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS ONE 2011, 6, e22119. [Google Scholar] [CrossRef]
  31. Gaetje, R.; Holtrich, U.; Engels, K.; Kissler, S.; Rody, A.; Karn, T.; Kaufmann, M. Differential expression of claudins in human endometrium and endometriosis. Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol. 2008, 24, 442–449. [Google Scholar] [CrossRef]
  32. Li, X.; Li, Y.; Qiu, H.; Wang, Y. Downregulation of claudin-7 potentiates cellular proliferation and invasion in endometrial cancer. Oncol. Lett. 2013, 6, 101–105. [Google Scholar] [CrossRef] [PubMed]
  33. Krikun, G. Endometriosis, angiogenesis and tissue factor. Scientifica 2012, 2012, 306830. [Google Scholar] [CrossRef] [PubMed]
  34. Sillem, M.; Prifti, S.; Koch, A.; Neher, M.; Jauckus, J.; Runnebaum, B. Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001, 95, 167–174. [Google Scholar] [CrossRef] [PubMed]
  35. Pino, M.; Galleguillos, C.; Torres, M.; Sovino, H.; Fuentes, A.; Boric, M.A.; Johnson, M.C. Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. Reproduction 2009, 138, 837–847. [Google Scholar] [CrossRef] [PubMed]
  36. Gilabert-Estellés, J.; Ramón, L.A.; España, F.; Gilabert, J.; Vila, V.; Réganon, E.; Castelló, R.; Chirivella, M.; Estellés, A. Expression of angiogenic factors in endometriosis: Relationship to fibrinolytic and metalloproteinase systems. Hum. Reprod. 2007, 22, 2120–2127. [Google Scholar] [CrossRef] [PubMed]
  37. Majewska, N.; Zaręba, I.; Surażyński, A.; Galicka, A. Methylparaben-induced decrease in collagen production and viability of cultured human dermal fibroblasts. J. Appl. Toxicol. JAT 2017, 37, 1117–1124. [Google Scholar] [CrossRef]
  38. Khanna, S.; Dash, P.R.; Darbre, P.D. Exposure to parabens at the concentration of maximal proliferative response increases migratory and invasive activity of human breast cancer cells in vitro. J. Appl. Toxicol. JAT 2014, 34, 1051–1059. [Google Scholar] [CrossRef]
  39. Ptak, A.; Hoffmann, M.; Gruca, I.; Barć, J. Bisphenol A induce ovarian cancer cell migration via the MAPK and PI3K/Akt signalling pathways. Toxicol. Lett. 2014, 229, 357–365. [Google Scholar] [CrossRef]
  40. Fritz, G.; Brachetti, C.; Bahlmann, F.; Schmidt, M.; Kaina, B. Rho GTPases in human breast tumours: Expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer 2002, 87, 635–644. [Google Scholar] [CrossRef]
  41. Zhao, Y.; Itoh, S.; Wang, X.; Isaji, T.; Miyoshi, E.; Kariya, Y.; Miyazaki, K.; Kawasaki, N.; Taniguchi, N.; Gu, J. Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions. J. Biol. Chem. 2006, 281, 38343–38350. [Google Scholar] [CrossRef] [PubMed]
  42. Wang, X.; Gu, J.; Ihara, H.; Miyoshi, E.; Honke, K.; Taniguchi, N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J. Biol. Chem. 2006, 281, 2572–2577. [Google Scholar] [CrossRef] [PubMed]
  43. Liu, X.; Zhou, B.; Xue, L.; Yen, F.; Chu, P.; Un, F.; Yen, Y. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin. Color. Cancer 2007, 6, 374–381. [Google Scholar] [CrossRef]
  44. Yang, B.; Wang, T.; Li, N.; Zhang, W.; Hu, Y. The High Expression of RRM2 Can Predict the Malignant Transformation of Endometriosis. Adv. Ther. 2021, 38, 5178–5190. [Google Scholar] [CrossRef] [PubMed]
  45. Wang, J.H.; Zhou, W.W.; Cheng, S.T.; Liu, B.X.; Liu, F.R.; Song, J.Q. Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells. Mol. Med. Rep. 2015, 12, 1810–1816. [Google Scholar] [CrossRef] [PubMed]
  46. Mei, Y.; Bian, C.; Li, J.; Du, Z.; Zhou, H.; Yang, Z.; Zhao, R.C. miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation. J. Cell. Biochem. 2013, 114, 1374–1384. [Google Scholar] [CrossRef]
  47. García-Gómez, E.; Vázquez-Martínez, E.R.; Reyes-Mayoral, C.; Cruz-Orozco, O.P.; Camacho-Arroyo, I.; Cerbón, M. Regulation of Inflammation Pathways and Inflammasome by Sex Steroid Hormones in Endometriosis. Front. Endocrinol. 2019, 10, 935. [Google Scholar] [CrossRef]
  48. Sherwin, J.R.; Sharkey, A.M.; Mihalyi, A.; Simsa, P.; Catalano, R.D.; D’Hooghe, T.M. Global gene analysis of late secretory phase, eutopic endometrium does not provide the basis for a minimally invasive test of endometriosis. Hum. Reprod. 2008, 23, 1063–1068. [Google Scholar] [CrossRef]
  49. Monsivais, D.; Bray, J.D.; Su, E.; Pavone, M.E.; Dyson, M.T.; Navarro, A.; Kakinuma, T.; Bulun, S.E. Activated glucocorticoid and eicosanoid pathways in endometriosis. Fertil. Steril. 2012, 98, 117–125. [Google Scholar] [CrossRef]
  50. Linares, R.; Fernández, M.F.; Gutiérrez, A.; García-Villalba, R.; Suárez, B.; Zapater, P.; Martínez-Blázquez, J.A.; Caparrós, E.; Tomás-Barberán, F.A.; Francés, R. Endocrine disruption in Crohn’s disease: Bisphenol A enhances systemic inflammatory response in patients with gut barrier translocation of dysbiotic microbiota products. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2021, 35, e21697. [Google Scholar] [CrossRef]
  51. Taylor, R.N.; Lebovic, D.I.; Mueller, M.D. Angiogenic factors in endometriosis. Ann. N. Y. Acad. Sci. 2002, 955, 89–100. [Google Scholar] [CrossRef]
  52. McLaren, J.; Prentice, A.; Charnock-Jones, D.S.; Millican, S.A.; Müller, K.H.; Sharkey, A.M.; Smith, S.K. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Investig. 1996, 98, 482–489. [Google Scholar] [CrossRef] [PubMed]
  53. Prashanth, T.; Thirusangu, P.; Avin, B.R.V.; Ranganatha, V.L.; Prabhakar, B.T.; Khanum, S.A. Synthesis and evaluation of novel benzophenone-thiazole derivatives as potent VEGF-A inhibitors. Eur. J. Med. Chem. 2014, 87, 274–283. [Google Scholar] [CrossRef] [PubMed]
  54. Segovia-Mendoza, M.; de León, C.T.G.; García-Becerra, R.; Ambrosio, J.; Nava-Castro, K.E.; Morales-Montor, J. The chemical environmental pollutants BPA and BPS induce alterations of the proteomic profile of different phenotypes of human breast cancer cells: A proposed interactome. Environ. Res. 2020, 191, 109960. [Google Scholar] [CrossRef] [PubMed]
  55. Helmestam, M.; Davey, E.; Stavreus-Evers, A.; Olovsson, M. Bisphenol A affects human endometrial endothelial cell angiogenic activity in vitro. Reprod. Toxicol. 2014, 46, 69–76. [Google Scholar] [CrossRef]
  56. Zhu, H.; Xiao, X.; Zheng, J.; Zheng, S.; Dong, K.; Yu, Y. Growth-promoting effect of bisphenol A on neuroblastoma in vitro and in vivo. J. Pediatr. Surg. 2009, 44, 672–680. [Google Scholar] [CrossRef]
  57. Attar, E.; Tokunaga, H.; Imir, G.; Yilmaz, M.B.; Redwine, D.; Putman, M.; Gurates, B.; Attar, R.; Yaegashi, N.; Hales, D.B.; et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J. Clin. Endocrinol. Metab. 2009, 94, 623–631. [Google Scholar] [CrossRef]
  58. Greene, A.D.; Lang, S.A.; Kendziorski, J.A.; Sroga-Rios, J.M.; Herzog, T.J.; Burns, K.A. Endometriosis: Where are we and where are we going? Reproduction 2016, 152, R63–R78. [Google Scholar] [CrossRef]
  59. Zeitoun, K.M.; Bulun, S.E. Aromatase: A key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil. Steril. 1999, 72, 961–969. [Google Scholar] [CrossRef]
  60. Tang, Z.R.; Zhang, R.; Lian, Z.X.; Deng, S.L.; Yu, K. Estrogen-Receptor Expression and Function in Female Reproductive Disease. Cells 2019, 8, 1123. [Google Scholar] [CrossRef]
  61. Williams, G.P.; Darbre, P.D. Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells. Mol. Cell. Endocrinol. 2019, 486, 55–64. [Google Scholar] [CrossRef] [PubMed]
  62. Todorow, V.; Rahmeh, M.; Hofmann, S.; Kirn, V.; Mahner, S.; Jeschke, U.; von Schönfeldt, V. Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue. Arch. Gynecol. Obstet. 2017, 296, 269–276. [Google Scholar] [CrossRef] [PubMed]
  63. Attar, E.; Bulun, S.E. Aromatase and other steroidogenic genes in endometriosis: Translational aspects. Hum. Reprod. Update 2006, 12, 49–56. [Google Scholar] [CrossRef] [PubMed]
  64. Cao, J.; Rebuli, M.E.; Rogers, J.; Todd, K.L.; Leyrer, S.M.; Ferguson, S.A.; Patisaul, H.B. Prenatal bisphenol A exposure alters sex-specific estrogen receptor expression in the neonatal rat hypothalamus and amygdala. Toxicol. Sci. Off. J. Soc. Toxicol. 2013, 133, 157–173. [Google Scholar] [CrossRef] [PubMed]
  65. Yu, X.; Wang, Y.; Tan, X.; Li, M. Upregulation of fibroblast growth factor 2 contributes to endometriosis through SPRYs/DUSP6/ERK signaling pathway. Acta Histochem. 2021, 123, 151749. [Google Scholar] [CrossRef] [PubMed]
  66. Canis, M.; Donnez, J.G.; Guzick, D.S.; Halme, J.K.; Rock, J.A.; Schenken, R.S.; Vernon, M.W. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil. Steril. 1997, 67, 817–821. [Google Scholar]
  67. Roy, D.; Morgan, M.; Yoo, C.; Deoraj, A.; Roy, S.; Yadav, V.K.; Garoub, M.; Assaggaf, H.; Doke, M. Integrated Bioinformatics, Environmental Epidemiologic and Genomic Approaches to Identify Environmental and Molecular Links between Endometriosis and Breast Cancer. Int. J. Mol. Sci. 2015, 16, 25285–25322. [Google Scholar] [CrossRef] [PubMed]
  68. Chung, H.W.; Wen, Y.; Choi, E.A.; Hao, L.; Moon, H.S.; Yu, H.K.; Polan, M.L. Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis. Mol. Hum. Reprod. 2002, 8, 350–355. [Google Scholar] [CrossRef]
  69. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
  70. Vela-Soria, F.; Ballesteros, O.; Zafra-Gómez, A.; Ballesteros, L.; Navalón, A. UHPLC-MS/MS method for the determination of bisphenol A and its chlorinated derivatives, bisphenol S, parabens, and benzophenones in human urine samples. Anal. Bioanal. Chem. 2014, 406, 3773–3785. [Google Scholar] [CrossRef]
Table 1. Gene expression levels in endometriotic tissue (n = 33).
Table 1. Gene expression levels in endometriotic tissue (n = 33).
Cell PathwayGenenFD (%)AE (%)MeanSt. Dev.Percentiles
255075
Cell adhesionITGB23310098.02.375.710.420.852.26
CLDN73310098.01.592.720.560.951.62
Invasion, migration and metastasisMMP12163.698.010.7654.08n.e.0.030.31
MMP7412.197.01.015.31n.e.n.e.n.e.
FUT81133.398.00.732.89n.e.n.e.0.01
RRM23310096.02.799.270.510.911.59
MDK1443.4100.00.290.94n.e.n.e.0.02
RHOB3310096.05.1818.490.360.752.09
SPRY22163.691.00.420.72n.e.0.220.52
InflammationIL1R2412.198.03.1810.990.040.280.92
IL1RL12781.898.00.301.19n.e.n.e.n.e.
IL6ST33100104.07.6033.930.340.751.62
NR3C13090.999.012.0857.290.110.532.16
TNFRSF1B1133.3101.00.793.11n.e.n.e.n.e.
AngiogenesisANG3310096.02.717.760.490.881.98
ANGPT12884.8100.01.593.850.040.431.36
sVEGFR-12369.797.05.8232.28n.e.0.070.20
VEGFA2369.7101.01.051.19n.e.0.651.56
Cell proliferation and hormonal stimulationCYP19A1515.2102.02.2212.01n.e.n.e.n.e.
DUSP63193.999.05.917.880.033.008.37
ERα3310097.02.256.400.530.971.59
PGR13.096.00.000.01n.e.n.e.n.e.
STAR2884.894.08.3427.110.461.002.38
FD: frequency of detection; AE: amplification efficiency; St. Dev.: standard deviation; ITGB2: integrin beta-2; CLDN7: claudin 7; MMP1: matrix metallopeptidase 1; MMP7: matrix metallopeptidase 7; FUT8: fucosyltransferase 8; RRM2: ribonucleotide reductase M2; MDK: midkine; RHOB: ras homolog gene family, member B; SPRY2: sprout homolog 2; IL1RL1: interleukin 1 receptor, type I; IL1R2: interleukin 1 receptor, type II; IL6ST: interleukin 6 cytokine family signal transducer; NR3C1: nuclear receptor subfamily 3 group C member 1; TNFRSF1B: tumor necrosis factor receptor superfamily member 1B; ANG: angiogenin; ANGPT1: angiopoietin 1; sVEGFR-1: soluble vascular endothelial growth factor receptor-1; VEGFA: vascular endothelial growth factor A; CYP19A1: cytochrome P450 family 19 subfamily A member 1; DUSP6: dual specificity phosphatase 6; ERα: estrogen receptor 1; PGR: progesterone receptor; STAR: steroidogenic acute regulatory protein.; n.e.: not expressed.
Table 2. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in cell adhesion (n = 22).
Table 2. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in cell adhesion (n = 22).
ITGB2 CLDN7
β95% CIp-Value β95% CIp-Value
Parabens
MeP0.300.110.490.004 0.170.020.320.026
<39.26 ng/mL 0.00-- 0.00--
>39.26 ng/mL 1.130.361.900.006 0.850.351.350.002
EtP0.230.050.400.013 0.08−0.060.210.260
<4.51 ng/mL 0.00-- 0.00--
>4.51 ng/mL 0.74−0.131.610.091 −0.11−0.930.710.780
PrP0.04−0.180.250.723 0.01−0.140.160.869
<2.54 ng/mL 0.00-- 0.00--
>2.54 ng/mL −0.01−0.950.930.986 −0.22−0.860.420.478
BuP0.17−0.190.530.343 0.15−0.050.350.135
<0.14 ng/mL 0.00-- 0.00--
>0.14 ng/mL 1.070.052.090.040 0.910.211.620.014
ΣPBs0.290.080.510.011 0.180.020.330.029
<53.31 ng/mL 0.00-- 0.00--
>53.31 ng/mL 0.850.011.700.049 0.670.111.230.022
Benzophenones
BP-10.10−0.450.660.697 −0.24−0.530.050.101
<1.42 ng/mL 0.00-- 0.00--
>1.42 ng/mL 0.70−0.391.780.848 0.06−0.760.880.882
BP-30.04−0.380.460.848 −0.16−0.380.060.150
<2.53 ng/mL 0.00-- 0.00--
>2.53 ng/mL 0.48−0.631.590.380 −0.10−0.910.720.810
4-OHBP0.06−0.650.760.870 −0.13−0.520.250.482
<0.73 ng/mL 0.00-- 0.00--
>0.73 ng/mL −0.17−1.300.960.754 0.12−0.700.940.768
ΣBPs0.07−0.550.700.809 −0.28−0.610.040.079
<7.43 ng/mL 0.00-- 0.00--
>7.43 ng/mL 0.63−0.471.720.245 −0.16−0.970.660.696
CI: confidence interval; MeP: methylparaben; EtP: ethylparaben; PrP: propylparaben; BuP: butylparaben; ΣPB: sum of parabens; BP-1: benzophenone-1; BP-3: benzophenone-3; 4-OHBP: 4-hydroxibenzophenone; ΣBP: sum of benzophenones; ITGB2: integrin beta-2; CLDN7: claudin 7.
Table 3. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in invasion, migration, and metastasis (n = 22).
Table 3. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in invasion, migration, and metastasis (n = 22).
MMP1 FUT8 RRM2
OR95% CIp-Value OR95% CIp-Value β95% CIp-Value
Parabens
MeP2.961.147.720.026 0.900.551.460.668 0.10−0.0940.3030.283
<39.26 ng/mL 1.00-- 1.00-- 0.00--
>39.26 ng/mL 12.001.12128.840.040 0.660.114.000.648 0.63−0.101.360.088
EtP1.270.831.950.277 1.170.771.760.466 0.09−0.720.260.252
<4.51 ng/mL 1.00-- 1.00-- 0.00--
>34.51 ng/mL 3.750.5426.050.181 3.750.5426.050.181 0.41−0.361.180.280
PrP1.630.932.840.086 1.260.811.960.306 0.05−0.140.230.609
<2.54 ng/mL 1.00-- 1.00-- 0.00--
>2.54 ng/mL 1.520.259.300.648 12.001.12128.840.040 0.18−0.610.960.647
BuP1.460.732.190.285 0.670.331.350.262 0.03−0.230.290.827
<0.14 ng/mL 1.00-- 1.00-- 0.00--
>0.14 ng/mL 5.000.7035.500.108 1.170.197.120.867 0.71−0.341.750.174
ΣPBs2.680.096.590.031 0.930.561.520.760 0.10−0.110.320.317
<53.31 ng/mL 1.00-- 1.00-- 0.00--
>53.31 ng/mL 12.001.12128.840.040 0.660.114.000.648 0.33−0.451.100.387
Benzophenones
BP-10.590.221.550.281 1.410.563.540.467 0.077−0.3020.4550.677
<1.42 ng/mL 1.00-- 1.00-- 0.00--
>1.42 ng/mL 0.660.114.000.648 1.520.259.300.648 0.44−0.321.210.239
BP-31.230.632.390.542 1.060.542.090.872 −0.13−0.420.150.343
<2.53 ng/mL 1.00-- 1.00-- 0.00--
>2.53 ng/mL 1.520.259.300.648 3.750.5426.0450.181 0.40−0.671.480.443
4-OHBP1.860.556.340.322 1.4760.4754.5830.501 −0.13−0.6040.3520.587
<0.73 ng/mL 1.00-- 1.00-- 0.00--
>0.73 ng/mL 1.520.250.300.648 1.520.259.300.648 −0.44−1.200.320.243
ΣBPs1.220.020.880.036 1.290.473.580.620 −0.07−0.500.350.725
<7.43 ng/mL 1.00-- 1.00-- 0.00--
>7.43 ng/mL 0.660.114.000.648 1.520.259.300.648 0.55−0.511.610.289
MDK RHOB SPRY2
OR95% CIp-value β95% CIp-value OR95% CIp-value
Parabens
MeP0.770.471.270.309 0.270.110.430.002 0.480.240.970.040
<39.26 ng/mL 1.00-- 0.00-- 1.00--
>39.26 ng/mL 0.450.082.670.379 1.020.081.960.035 0.310.051.850.200
EtP0.880.601.310.529 0.180.030.320.022 0.890.601.300.535
<4.51 ng/mL 1.00-- 0.00-- 1.00--
>34.51 ng/mL 1.000.185.681.000 0.30−0.761.350.565 1.460.268.050.665
PrP0.940.621.420.772 0.11−0.070.280.206 0.790.521.210.274
<2.54 ng/mL 1.00-- 0.00-- 1.00--
>2.54 ng/mL 1.000.185.681.000 −0.50−1.840.830.441 0.690.123.780.665
BuP0.720.381.360.308 0.400.110.690.010 0.630.341.160.137
<0.14 ng/mL 1.00-- 0.00-- 1.00--
>0.14 ng/mL 0.750.134.290.746 1.680.562.790.005 0.430.072.500.346
ΣPBs0.760.451.270.293 0.280.120.450.002 0.510.260.980.044
<53.31 ng/mL 1.00-- 0.00-- 1.00--
>53.31 ng/mL 0.450.082.670.379 1.110.192.030.021 0.310.051.850.200
Benzophenones
BP-10.710.301.700.438 −0.02−0.420.380.923 1.030.452.350.954
<1.42 ng/mL 1.00-- 0.00-- 1.00--
>1.42 ng/mL 0.450.082.670.379 0.30−1.061.650.653 0.690.123.780.665
BP-30.830.431.580.567 0.03−0.360.420.865 0.830.421.610.572
<2.53 ng/mL 1.00-- 0.00-- 1.00--
>2.53 ng/mL 2.220.3813.180.379 0.85−0.452.150.187 1.460.268.050.665
4-OHBP0.440.131.530.197 0.234−0.2670.7350.340 0.700.242.050.510
<0.73 ng/mL 1.00-- 0.00-- 1.00--
>0.73 ng/mL 1.000.185.681.000 0.04−1.321.400.947 0.690.123.780.665
ΣBPs0.820.312.150.689 −0.01−0.440.420.957 0.980.382.510.967
<7.43 ng/mL 1.00-- 0.00-- 1.00--
>7.43 ng/mL 0.450.082.670.379 0.85−0.342.040.151 0.690.123.780.665
OR: odds ratio; CI: confidence interval; MeP: methylparaben; EtP: ethylparaben; PrP: propylparaben; BuP: butylparaben; ΣPB: sum of parabens; BP-1: benzophenone-1; BP-3: benzophenone-3; 4-OHBP: 4-hydroxibenzophenone; ΣBP: sum of benzophenones; MMP1: matrix metallopeptidase 1; FUT8: fucosyltransferase 8; RRM2: ribonucleotide reductase M2; MDK: midkine; RHOB: ras homolog gene family, member B; SPRY2: sprout homolog 2.
Table 4. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in inflammation (n = 22).
Table 4. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in inflammation (n = 22).
IL1RL1 IL6ST NR3C1 TNFRSF1B
β95% CIp-Value β95% CIp-Value β95% CIp-Value OR95% CIp-Value
Parabens
MeP−0.21−0.770.350.440 0.350.120.580.005 0.570.131.020.014 0.810.471.370.426
<39.26 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>39.26 ng/mL 2.00−2.326.310.345 1.260.382.130.007 1.09−1.053.220.300 0.390.062.770.346
EtP−0.12−0.580.330.575 0.230.070.400.008 0.30−0.070.670.107 0.990.651.490.950
<4.51 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>34.51 ng/mL −1.32−3.310.670.179 0.25−0.801.310.620 −0.42−2.611.770.692 1.000.156.531.000
PrP−0.20−0.690.290.391 0.05−0.190.290.662 0.21−0.210.630.305 1.020.661.590.929
<2.54 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>2.54 ng/mL −1.31−5.683.060.538 −0.42−1.861.020.549 −0.69−2.861.480.513 2.570.3618.330.346
BuP0.43−0.201.060.165 0.470.200.730.002 0.740.271.210.004 0.420.151.180.101
<0.14 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>0.14 ng/mL 3.91−0.087.910.055 1.710.492.940.008 2.610.784.440.007 0.300.042.170.232
ΣPBs−0.25−0.830.330.379 0.360.130.600.004 0.600.141.050.013 0.780.451.360.379
<53.31 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>53.31 ng/mL 2.29−1.996.570.278 1.270.402.140.006 1.26−0.853.370.225 0.390.062.770.346
Benzophenones
BP-1−0.13−1.190.930.797 −0.03−0.500.440.886 −0.33−1.260.590.459 0.580.211.620.298
<1.42 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>1.42 ng/mL −1.39−4.972.190.425 0.32−1.131.770.649 −1.18−4.742.390.499 2.570.3618.330.346
BP-3−0.17−1.100.770.714 −0.03−0.420.360.862 0.31−0.481.090.428 10.091.3476.290.025
<2.53 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>2.53 ng/mL 2.31−2.457.060.324 0.60−0.832.030.389 2.15−1.325.620.211 11.001.05120.400.049
4-OHBP2.23−0.575.030.112 −0.04−0.690.610.895 0.31−0.781.400.555 1.580.485.170.452
<0.73 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>0.73 ng/mL 4.710.369.060.035 0.17−1.291.620.810 1.87−1.635.380.278 1.000.156.531.000
ΣBPs−0.15−1.461.160.812 −0.13−0.640.380.593 −0.35−1.570.870.558 14.151.27157.400.031
<7.43 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>7.43 ng/mL 1.87−1.675.420.281 0.40−1.041.840.569 0.54−1.652.710.614 8.330.7889.470.080
OR: odds ratio; CI: confidence interval; MeP: methylparaben; EtP: ethylparaben; PrP: propylparaben; BuP: butylparaben; ΣPB: sum of parabens; BP-1: benzophenone-1; BP-3: benzophenone-3; 4-OHBP: 4-hydroxibenzophenone; ΣBP: sum of benzophenones; IL1RL1: interleukin 1 receptor, type I; IL6ST: interleukin 6 cytokine family signal transducer; NR3C1: nuclear receptor subfamily 3 group C member 1; TNFRSF1B: tumor necrosis factor receptor superfamily member 1B.2.2.4. Markers of Angiogenesis.
Table 5. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in angiogenesis (n = 22).
Table 5. Associations between urinary concentrations of PBs and BPs and expression levels of genes involved in angiogenesis (n = 22).
ANG ANGPT1 sVEFGR-1 VEGFA
β95% CIp-Value β95% CIp-Value β95% CIp-Value OR95% CIp-Value
Parabens
MeP0.22−0.010.460.062 0.490.180.810.004 1.530.872.670.139 0.880.531.440.602
<39.26 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>39.26 ng/mL 0.990.141.840.025 1.620.272.970.021 2.220.3813.180.379 1.000.156.531.000
EtP0.15−0.050.350.141 0.22−0.100.550.160 1.140.771.690.508 0.820.531.270.369
<4.51 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>34.51 ng/mL 0.35−0.851.550.549 0.15−1.431.730.842 2.220.3813.180.379 0.120.011.290.080
PrP0.14−0.080.350.201 0.26−0.090.600.132 1.861.013.400.045 0.850.541.330.465
<2.54 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>2.54 ng/mL 0.21−1.001.410.722 0.38−1.191.950.620 5.400.7837.510.088 0.390.062.770.346
BuP0.24−0.020.510.071 −0.25−1.811.300.736 1.150.642.0730.650 0.950.511.750.865
<0.14 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>0.14 ng/mL 0.94−0.202.070.100 −2.04−6.692.610.371 7.501.0454.120.046 0.500.073.550.488
ΣPBs0.23−0.010.480.063 0.510.190.840.004 1.540.872.740.140 0.890.531.490.664
<53.31 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>53.31 ng/mL 0.58−0.601.760.320 1.780.493.070.010 2.220.3813.180.379 1.000.156.531.000
Benzophenones
BP-10.05−0.420.520.837 −0.55−1.230.130.103 1.080.462.520.865 0.670.251.780.419
<1.42 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>1.42 ng/mL 0.680.481.840.240 0.48−4.255.200.836 2.220.3813.180.379 0.120.011.290.080
BP-30.03−0.320.390.843 0.05−0.600.700.879 0.760.371.560.453 0.550.221.410.215
<2.53 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>2.53 ng/mL 0.79−0.361.940.169 0.53−1.032.090.482 2.220.3813.180.379 0.120.011.290.080
4-OHBP−0.25−0.830.340.388 −0.15−1.180.890.767 1.470.484.550.501 1.160.353.770.810
<0.73 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>0.73 ng/mL −0.16−1.371.040.779 −0.03−1.621.550.964 2.220.3813.180.379 2.570.3618.330.346
ΣBPs0.03−0.490.560.894 −0.43−1.300.450.316 0.800.302.130.654 0.500.151.630.250
<7.43 ng/mL 0.00-- 0.00-- 0.00-- 1.00--
>7.43 ng/mL 0.47−0.721.660.421 0.83−2.554.200.613 1.000.185.681.000 0.390.062.770.346
OR: odds ratio; CI: confidence interval; MeP: methylparaben; EtP: ethylparaben; PrP: propylparaben; BuP: butlparaben; ΣPB: sum of parabens; BP-1: benzophenone-1; BP-3: benzophenone-3; 4-OHBP: 4-hydroxibenzophenone; ΣBP: sum of benzophenones; ANG: angiogenin; ANGPT1: angiopoietin 1; sVEGFR-1: soluble vascular endothelial growth factor receptor-1; VEGFA: vascular endothelial growth factor A.2.2.5. Markers of Cell Proliferation and Hormonal Stimulation.
Table 6. Associations between low and high urinary concentrations of PBs and BPs and expression levels of genes involved in cell proliferation and hormonal stimulation (n = 22).
Table 6. Associations between low and high urinary concentrations of PBs and BPs and expression levels of genes involved in cell proliferation and hormonal stimulation (n = 22).
DUSP6 ERα STAR
β95% CIp-Value β95% CIp-Value β95% CIp-Value
Parabens
MeP−0.90−1.49−0.300.005 0.180.040.310.015 −1.35−2.9080.210.086
<39.26 ng/mL 0.00-- 0.00-- 0.00--
>39.26 ng/mL −3.13−6.990.730.106 0.780.301.260.003 −5.64−11.08−0.200.043
EtP0.01−0.630.650.968 0.10−0.110.210.074 −0.51−1.840.830.437
<4.51 ng/mL 0.00-- 0.00-- 0.00--
>34.51 ng/mL −1.74−6.523.030.450 0.29−0.310.870.325 0.02−6.026.060.994
PrP0.16−0.560.890.640 0.06−0.080.190.406 −0.07−1.311.160.902
<2.54 ng/mL 0.00-- 0.00-- 0.00--
>2.54 ng/mL −1.38−6.183.420.560 0.05−0.560.650.871 0.38−5.666.420.898
BuP−0.49−1.650.680.391 0.16−0.020.350.076 0.57−1.252.390.520
<0.14 ng/mL 0.00-- 0.00-- 0.00--
>0.14 ng/mL −3.01−7.671.640.192 0.700.191.200.009 1.50−4.537.520.610
ΣPBs−0.83−1.46−0.190.014 0.190.050.330.011 −1.28−2.820.270.100
<53.31 ng/mL 0.00-- 0.00-- 0.00--
>53.31 ng/mL 1.37−8.240.810.102 0.390.211.210.008 −3.47−9.292.350.228
Benzophenones
BP-10.97−0.282.210.122 −0.09−0.350.170.463 2.940.385.500.027
<1.42 ng/mL 0.00-- 0.00-- 0.00--
>1.42 ng/mL 1.37−3.436.180.558 0.39−0.501.290.372 4.20−1.519.920.140
BP-30.17−0.851.180.737 −0.12−0.330.100.262 0.41−1.682.510.683
<2.53 ng/mL 0.00-- 0.00-- 0.00--
>2.53 ng/mL −0.05−4.904.790.982 −0.01−0.920.910.988 2.45−3.498.380.400
4-OHBP−0.30−2.001.400.713 0.02−0.350.390.923 2.53−0.925.980.141
<0.73 ng/mL 0.00-- 0.00-- 0.00--
>0.73 ng/mL −0.47−5.314.370.841 −0.01−0.620.600.971 5.940.9410.930.022
ΣBPs0.85−0.602.290.234 −0.17−0.490.150.273 2.10−0.845.030.151
<7.43 ng/mL 0.00-- 0.00-- 0.00--
>7.43 ng/mL −0.58−5.414.260.807 0.09−0.821.010.832 4.61−0.709.920.085
CI: confidence interval; MeP: methylparaben; EtP: ethylparaben; PrP: propylparaben; BuP: butylparaben; ΣPB: sum of parabens; BP-1: benzophenone-1; BP-3: benzophenone-3; 4-OHBP: 4-hydroxibenzophenone; ΣBP: sum of benzophenones; DUSP6: dual specificity phosphatase 6; ERα: estrogen receptor 1; STAR: steroidogenic acute regulatory protein.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Peinado, F.M.; Olivas-Martínez, A.; Lendínez, I.; Iribarne-Durán, L.M.; León, J.; Fernández, M.F.; Sotelo, R.; Vela-Soria, F.; Olea, N.; Freire, C.; et al. Expression Profiles of Genes Related to Development and Progression of Endometriosis and Their Association with Paraben and Benzophenone Exposure. Int. J. Mol. Sci. 2023, 24, 16678. https://doi.org/10.3390/ijms242316678

AMA Style

Peinado FM, Olivas-Martínez A, Lendínez I, Iribarne-Durán LM, León J, Fernández MF, Sotelo R, Vela-Soria F, Olea N, Freire C, et al. Expression Profiles of Genes Related to Development and Progression of Endometriosis and Their Association with Paraben and Benzophenone Exposure. International Journal of Molecular Sciences. 2023; 24(23):16678. https://doi.org/10.3390/ijms242316678

Chicago/Turabian Style

Peinado, Francisco M., Alicia Olivas-Martínez, Inmaculada Lendínez, Luz M. Iribarne-Durán, Josefa León, Mariana F. Fernández, Rafael Sotelo, Fernando Vela-Soria, Nicolás Olea, Carmen Freire, and et al. 2023. "Expression Profiles of Genes Related to Development and Progression of Endometriosis and Their Association with Paraben and Benzophenone Exposure" International Journal of Molecular Sciences 24, no. 23: 16678. https://doi.org/10.3390/ijms242316678

APA Style

Peinado, F. M., Olivas-Martínez, A., Lendínez, I., Iribarne-Durán, L. M., León, J., Fernández, M. F., Sotelo, R., Vela-Soria, F., Olea, N., Freire, C., Ocón-Hernández, O., & Artacho-Cordón, F. (2023). Expression Profiles of Genes Related to Development and Progression of Endometriosis and Their Association with Paraben and Benzophenone Exposure. International Journal of Molecular Sciences, 24(23), 16678. https://doi.org/10.3390/ijms242316678

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop